A Study to Learn How the Study Medicine Called Ibuzatrelvir is Taken up into the Blood of Healthy Adults After Taking Different Tablets of the Study Medicine Called Ibuzatrelvir.

Start 7 Apr 2026 · Status Ongoing, recruiting · 1 EU/EEA countries · 1 sites · Protocol C5091029

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other

Status Ongoing, recruiting

Participants planned 18

Countries 1

Sites 1

Coronavirus disease 2019

Key facts

Sponsor: Pfizer Inc.
Participant type: Healthy volunteers
Age range: 18-64 years, 65+ years
Gender: Male and Female
Therapeutic area: Diseases [C] - Virus Diseases [C02]
Trial duration: 7 Apr 2026 → ongoing
Decision date (initial): 2026-04-01
Transition trial: No
Low-intervention: No
Rare-disease indication: No
Vulnerable population: Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Coronavirus disease 2019

Version	Level	Code	Term	System organ class
23.0	PT	10084268	COVID-19	100000004862

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Pfizer Inc.

Sponsor organisation: Pfizer Inc.
Address: 66 Hudson Boulevard East
City: New York
Postcode: 10001-2189
Country: United States

Scientific contact point

Organisation: Pfizer Inc.
Contact name: Clinical Medical Lead

Public contact point

Organisation: Pfizer Inc.
Contact name: Clinical Medical Lead

Locations

1 EU/EEA country · 1 investigational sites

By country

Country	MS status	Planned subjects	Sites
Belgium	Ongoing, recruiting	18	1
Rest of world	—	0	—

Investigational sites

Belgium

1 site · Ongoing, recruiting

Pfizer Clinical Research Unit

N/A, Route de Lennik 808, B-1070, Brussels

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country	Trial start	Trial end	Recruitment start	Recruitment end	Early termination
Belgium	2026-04-07		2026-04-13

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#	Type	Code	Submitted	Reference MS	Conclusion	Decision date
1	INITIAL	IN	2026-02-26	Belgium	Acceptable 2026-04-01	2026-04-01
2	NON SUBSTANTIAL MODIFICATION	NSM-1	2026-04-21	Belgium	Acceptable 2026-04-01	2026-04-21